AEON Biopharma prices $20M public offering of units and warrants to fund operations through 2025

AEON Biopharma, Inc.

Gross proceeds ~$20M from 40M units at $0.50/unit; each unit includes one share or Pre-Funded Warrant plus two Series A and B Warrants at $0.625 exercise.
Series A Warrants exercisable after stockholder approval, expire 60 months; Series B Warrants exercisable after approval, expire 30 months with cashless option.
Aegis Capital Corp. sole book-runner; underwriter has 45-day option to purchase up to 15% additional shares/warrants for over-allotments.
Expected close Jan 7, 2025; net proceeds for general corporate purposes and development of ABP-450 botulinum toxin biosimilar.
CEO Marc Forth: capital sufficient through 2025; plans BPD Type 2 meeting with FDA in 2025 to discuss next steps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.